Accelerating breakthrough therapeutics, diagnostics, and synthetic biology through strategic alliances, joint R&D, and global commercialization networks.
Flexible engagement structures designed to align with your stage of development, IP strategy, and commercialization goals.
Co-funded research programs combining our clinical infrastructure and regulatory expertise with your novel scientific platforms.
Streamlined option-to-license agreements for preclinical assets, with milestone-driven payments and worldwide commercial rights.
Integrated project management for Phase I-III trials, leveraging our global trial networks, data analytics, and CRO partnerships.
Corporate venture investments ranging from Series A to late-stage, paired with dedicated partnership managers and go-to-market support.
We are actively seeking partners and assets in the following high-impact biotechnology domains.
CRISPR-based editors, CAR-T expansions, AAV delivery optimization, and ex vivo manufacturing scalability.
Generative molecular design, target identification networks, ADMET prediction, and multi-omics integration.
Programmable bacterial chassis, biosynthetic pathways for pharma/agritech, and microbial fermentation platforms.
Liquid biopsy assays, NGS panel development, biomarker validation, and point-of-care rapid testing systems.
LNP formulations, peptide-drug conjugates, transdermal patches, and controlled-release hydrogel matrices.
Biofabrication, 3D bioprinting scaffolds, organoid models, and decellularized matrix applications.
Transparent, efficient, and scientifically rigorous from initial contact to commercial launch.
Submit your deck or technical summary via our secure portal. All submissions are reviewed under NDA within 5 business days.
Cross-functional review by our therapeutic area leaders, regulatory experts, and market access strategists.
Negotiation of milestones, exclusivity terms, IP ownership, and commercialization responsibilities.
Establishment of a Joint Steering Committee (JSC) with quarterly reviews, shared KPIs, and integrated project tracking.
Tell us about your platform, stage of development, and collaboration preferences. Our biotech partnership team will respond within 48 hours.